Gynecologic Oncology | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology

Featuring perspectives from Drs Michael Birrer and Kathleen Moore, including the following topics: Gynecologic Oncology   Introduction (0:00) Ovarian Cancer    PARP inhibitors as primary maintenance (8:11) PARP inhibitors for recurrent and metastatic disease (19:04) Antibody-drug conjugates: Mirvetuximab soravtansine; upifitamab rilsodotin (31:39) Endometrial Cancer   Immunotherapy for metastatic disease (43:49) Selinexor as maintenance therapy (51:33) Other novel agents (56:52) Cervical Cancer   Immunotherapy for metastatic disease and the antibody-drug conjugate tisotumab vedotin (1:01:00) CME information and select publications